Osimertinib Mesylate Patent Expiration

Osimertinib Mesylate is Used for treating locally advanced or metastatic non-small cell lung cancer with specific mutations in combination with chemotherapy. It was first introduced by Astrazeneca Pharmaceuticals Lp in its drug Tagrisso on Nov 13, 2015.


Osimertinib Mesylate Patents

Given below is the list of patents protecting Osimertinib Mesylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Tagrisso US10183020 Pharmaceutical compositions comprising AZD9291 Jan 02, 2035 Astrazeneca
Tagrisso US11524951 2-(2,4,5-substituted-anilino)pyrimidine compounds Jul 25, 2032 Astrazeneca
Tagrisso US8946235 2-(2,4,5-substituted-anilino) pyrimidine compounds Aug 08, 2032 Astrazeneca
Tagrisso US9732058 2-(2,4,5-substituted-anilino)pyrimidine compounds Jul 25, 2032 Astrazeneca


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Osimertinib Mesylate's patents.

Given below is the list recent legal activities going on the following patents of Osimertinib Mesylate.

Event Date Patent/Publication
Patent litigations
Patent Issue Date Used in PTA Calculation 13 Dec, 2022 US11524951
Recordation of Patent Grant Mailed 13 Dec, 2022 US11524951
Email Notification 23 Nov, 2022 US11524951
Issue Notification Mailed 22 Nov, 2022 US11524951
Application Is Considered Ready for Issue 31 Oct, 2022 US11524951
Dispatch to FDC 31 Oct, 2022 US11524951
Issue Fee Payment Received 28 Oct, 2022 US11524951
Issue Fee Payment Verified 28 Oct, 2022 US11524951
Electronic Review 21 Oct, 2022 US11524951
Mail Response to 312 Amendment (PTO-271) 20 Oct, 2022 US11524951



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳